Literature DB >> 27790587

Immunohistochemical Expression of Cyclin B1 in Epithelial Hyperplasia, Dysplasia and Oral Squamous Cell Carcinomas - A Comparative Study.

Kochli Channappa Niranjan1, Amsavardani Tayaar2, G S Kumar3, Rekha Krishnapillai4, Kaveri Hallikeri2, Santosh Hunasgi5.   

Abstract

INTRODUCTION: Cyclin B1 is important in the cell cycle progression from G2 to M phase. Cyclin B1 binds to CDC2, which then becomes dephosphorylated and gets relocated to the nucleus, ensuring the transition toward mitosis. AIM: Over expression of Cyclin B1, has been reported more recently in breast, colon, prostate, oral and esophageal carcinomas. Thus, the aim of the present study was to examine the expression of Cyclin B1 in hyperplasia, dysplasia and Oral Squamous Cell Carcinomas (OSCC).
MATERIALS AND METHODS: A total of 64 histopathologically diagnosed cases of epithelial hyperplasias, dysplastic oral epithelium and OSCC were included in the study. Immunohistochemical procedure was carried out using the monoclonal mouse Cyclin B1 antibody (Clone V-152). The Cyclin B1 positive tumor cells counted were expressed as percentage of positive tumor cells. Nuclear and cytoplasmic labeling index (n&cLI) were calculated. The results were tabulated and statistically analyzed by Kruskal Wallis test- One Way ANOVA and Mann Whitney U- test.
RESULTS: Combined n&cLI was considered only in 28.57% of epithelial hyperplasias, 40.7% of oral epithelial dysplasias and 72% of OSCC showed over expression of Cyclin B1 with p value being 0.029. Cyclin B1 expression was not significantly different between the grades of dysplasia, between the grades of OSCC and between the marginal groups.
CONCLUSION: The present study demonstrates more than 50% of the study group showing less than 20% of nuclear staining. The importance of such variations within a type of lesion requires further investigation, since Cyclin B1 has proved useful in many studies from esophageal and laryngeal squamous cell carcinoma as a prognostic indicator, an indicator of recurrence and as an indicator for tumor sensitivity to radiotherapy. Further studies are to be extended towards evaluating the role of Cyclin B1 as a prognostic indicator.

Entities:  

Keywords:  Carcinogenesis; Cell cycle regulators; Immunohistochemistry; Oral lesions

Year:  2016        PMID: 27790587      PMCID: PMC5072087          DOI: 10.7860/JCDR/2016/19820.8563

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  31 in total

1.  Nuclear localization of cyclin B1 regulates DNA damage-induced apoptosis.

Authors:  Lisa A Porter; I Howard Cukier; Jonathan M Lee
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

2.  Overexpression of cyclin B1 in human colorectal cancers.

Authors:  A Wang; N Yoshimi; N Ino; T Tanaka; H Mori
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 3.  Cell cycle checkpoints: preventing an identity crisis.

Authors:  S J Elledge
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

4.  Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation.

Authors:  J Li; A N Meyer; D J Donoghue
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

5.  p53 regulates a G2 checkpoint through cyclin B1.

Authors:  S A Innocente; J L Abrahamson; J P Cogswell; J M Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

6.  Expression of cyclins in ductal hyperplasia, atypical ductal hyperplasia and ductal carcinoma in situ of the breast.

Authors:  H J Kim; W H Jung; D Y Kim; H D Lee
Journal:  Yonsei Med J       Date:  2000-06       Impact factor: 2.759

7.  Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication.

Authors:  J C Soria; S J Jang; F R Khuri; K Hassan; D Liu; W K Hong; L Mao
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

8.  Proteic expression of p53 and cellular proliferation in oral leukoplakias.

Authors:  Antonio Santos-García; M Mar Abad-Hernández; Emilio Fonseca-Sánchez; Juan Jesús Cruz-Hernández; Agustín Bullón-Sopelana
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2005 Jan-Feb

9.  T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.

Authors:  Hiroyuki Suzuki; Daniel F Graziano; John McKolanis; Olivera J Finn
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

10.  Nuclear localization of cyclin B1 controls mitotic entry after DNA damage.

Authors:  P Jin; S Hardy; D O Morgan
Journal:  J Cell Biol       Date:  1998-05-18       Impact factor: 10.539

View more
  1 in total

1.  Identification of core genes associated with prostate cancer progression and outcome via bioinformatics analysis in multiple databases.

Authors:  Yutao Wang; Jianfeng Wang; Kexin Yan; Jiaxing Lin; Zhenhua Zheng; Jianbin Bi
Journal:  PeerJ       Date:  2020-03-31       Impact factor: 2.984

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.